<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00435604</url>
  </required_header>
  <id_info>
    <org_study_id>HZ2-07-01</org_study_id>
    <nct_id>NCT00435604</nct_id>
  </id_info>
  <brief_title>A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase</brief_title>
  <official_title>Phase I Dose-Ranging Randomized Double-Blinded Controlled Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halozyme Therapeutics</source>
  <brief_summary>
    <textblock>
      This Phase I, randomized, double-blinded, within-subject controlled, two-way crossover study&#xD;
      comparing the time to inject (flow rate), safety, and tolerability of a subcutaneously (SC)&#xD;
      administered, viscous antibody solution of with and without human recombinant hyaluronidase&#xD;
      (rHuPH20) in volunteer subjects.&#xD;
&#xD;
      The study hypothesizes that the time required to complete a 20-mL SC injection of a viscous&#xD;
      antibody with rHuPH20 will be comparable or shorter than the time required for the injection&#xD;
      without rHuPH20.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to inject 20 mL of a viscous antibody solution with and without rHuPH20.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the time required for a subcutaneous injection with various doses of rHuPH20, safety, tolerability.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylenex</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteers of either sex, age 18 to 65 years, inclusive.&#xD;
&#xD;
          2. Intact normal skin on both upper extremities without tattoos or potentially obscuring&#xD;
             pigmentation or lesions.&#xD;
&#xD;
          3. Vital signs (BP, HR, temperature, respiratory rate) within normal range.&#xD;
&#xD;
          4. Metabolic panel (e.g., sodium, potassium, chloride, bicarbonate, BUN, creatinine,&#xD;
             glucose, calcium, AST, ALT, alkaline phosphatase, total bilirubin, albumin, and total&#xD;
             protein) within normal range within 7 days of injection.&#xD;
&#xD;
          5. A negative serum or urine pregnancy test (if female of child-bearing potential) within&#xD;
             7 days of injection.&#xD;
&#xD;
          6. Female subjects of child-bearing potential must be practicing effective birth control&#xD;
             or abstinence currently and plan to continue to do so for the duration of the study.&#xD;
&#xD;
          7. Decision-making capacity and willingness and ability to comply with the requirements&#xD;
             for full completion of the trial.&#xD;
&#xD;
          8. Willingness and ability to sign an informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Upper extremity edema.&#xD;
&#xD;
          2. Upper extremity pathology that could interfere with any protocol-specified outcome&#xD;
             assessment (e.g., cellulitis, lymphatic disorder or prior surgery, preexisting pain&#xD;
             syndrome, previous mastectomy and/or axillary lymph node dissection, etc.).&#xD;
&#xD;
          3. Contraindication to an antibody, such as known history of anaphylactic or severe&#xD;
             systemic reactions.&#xD;
&#xD;
          4. Known predisposition to renal insufficiency or renal failure, including diabetes&#xD;
             mellitus, volume depletion, sepsis, paraproteinemia, and subjects receiving known&#xD;
             nephrotoxic drugs.&#xD;
&#xD;
          5. Known allergy to hyaluronidase or any other ingredient in the formulation of Hylenex.&#xD;
&#xD;
          6. Known allergy to bee or vespid venom.&#xD;
&#xD;
          7. Known coagulopathy.&#xD;
&#xD;
          8. Pregnancy or breast-feeding woman.&#xD;
&#xD;
          9. Known clinically significant cardiovascular, gastrointestinal, hepatic, neurological,&#xD;
             psychiatric, endocrine, cancer, HIV infection, diabetes mellitus, intercurrent illness&#xD;
             such as influenza, or other major systemic disease that would unduly risk the&#xD;
             subject's safety or interfere with the interpretation of results.&#xD;
&#xD;
         10. Participation in a study of any investigational drug or device within 30 days of&#xD;
             enrollment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anoshie Ratnayake, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>February 14, 2007</study_first_submitted>
  <study_first_submitted_qc>February 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2007</study_first_posted>
  <last_update_submitted>October 13, 2011</last_update_submitted>
  <last_update_submitted_qc>October 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Richard Yocum, M.D., Vice President of Clinical Dev and Med Affairs</name_title>
    <organization>Halozyme Therapeutics</organization>
  </responsible_party>
  <keyword>hyaluronidase</keyword>
  <keyword>subcutaneous drug delivery</keyword>
  <keyword>Volunteer Subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

